6-hydroxynaphthalene-2-carboxamide | 62529-01-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-hydroxynaphthalene-2-carboxamide
• 英文别名: 6-Hydroxy-2-naphthamide
• CAS: 62529-01-5
• 化学式: C₁₁H₉NO₂
• 分子量: 187.198
• InChiKey: AHOQHQUHLVKLNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-hydroxynaphthalene-2-carboxamide 在 三氟乙酸酐 、 吡啶 作用下， 以 四氢呋喃 为溶剂， 反应 16.5h， 生成 6-氰基-2-萘酚
  参考文献：
  名称：

  3-Aryl-1,2,4-oxadiazole Derivatives Active Against Human Rhinovirus

  摘要：

  The human rhinovirus (hRV) is the causative agent of the common cold that often aggravates respiratory complications in patients with asthma or chronic obstructive pulmonary disease. The high rate of mutations and variety of serotypes are limiting the development of anti-hRV drugs, which emphasizes the need for the discovery of novel lead compounds. Previously, we identified antiviral compound 1 that we used here as the starting material for developing a novel compound series with high efficacy against hRV-A and -B. Improved metabolic stability was achieved by substituting an ester moiety with a 1,2,4-oxadiazole group. Specifically, compound 3k exhibited a high efficacy against hRV-B14, hRV-A21, and hRV-A71, with EC50 values of 66.0, 22.0, and 3.7 nM, respectively, and a relevant hepatic stability (59.6 and 40.7% compound remaining after 30 min in rat and human liver microsomes, respectively). An in vivo study demonstrated that 3k possessed a desirable pharmacokinetic profile with low systemic clearance (0.158 L.h(-1).Kg(-1)) and modest oral bioavailability (27.8%). Hence, 3k appears to be an interesting candidate for the development of antiviral lead compounds.

  DOI：

  10.1021/acsmedchemlett.8b00134
• 作为产物：
  描述：

  2-羟基-6-萘甲酸 在 碳酸氢铵 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 72.0h， 生成 6-hydroxynaphthalene-2-carboxamide
  参考文献：
  名称：

  Sulfonamide derivatives for the treatment of diseases

  摘要：

  该发明涉及公式（1）的化合物，以及用于制备、用于制备的中间体、含有和使用这些衍生物的组合物的过程。根据本发明的化合物在许多疾病、紊乱和状况中具有用途，特别是在炎症性、过敏性和呼吸系统疾病、紊乱和状况中。

  公开号：

  US20050182091A1

文献信息

• Synthesis of <i>o</i>-Carboxyarylacrylic Acids by Room Temperature Oxidative Cleavage of Hydroxynaphthalenes and Higher Aromatics with Oxone
  作者：Keshaba Nanda Parida、Jarugu Narasimha Moorthy

  DOI：10.1021/acs.joc.5b00292

  日期：2015.8.21

  A simple procedure for the synthesis of a variety of o-carboxyarylacrylic acids has been developed with Oxone (2KHSO5·KHSO4·K2SO4); the oxidation reaction involves the stirring of methoxy/hydroxy-substituted naphthalenes, phenanthrenes, anthracenes, etc. with Oxone in an acetonitrile–water mixture (1:1, v/v) at rt. Mechanistically, the reaction proceeds via initial oxidation of naphthalene to o-quinone

  已经用Oxone（2KHSO 5 ·KHSO 4 ·K 2 SO 4）开发了一种简单的合成多种邻-羧基芳基丙烯酸的方法。氧化反应包括在室温下将乙氧基/羟基取代的萘，菲，蒽等与Oxone在乙腈-水混合物（1：1，v / v）中搅拌。从机理上讲，该反应是通过将萘初始氧化为邻醌而进行的，该邻苯醌会裂解成相应的邻羧基芳基丙烯酸。发现高级芳族化合物产生衍生自最初形成的邻-羧基芳基丙烯酸的羧甲基内酯。
• Method for preparing 2-hydroxy-6-ureidocarbonyl naphthalene derivative
  申请人：KABUSHIKI KAISHA UENO SEIYAKU OYO KENKYUJO

  公开号：EP1564206A1

  公开（公告）日：2005-08-17

  Disclosed is a method for preparing a 2-hydroxy-6-ureidocarbonyl naphthalene derivative. The method comprises the step of reacting 2-hydroxy-6-aminocarbonyl naphthalene and a isocyanate in an organic solvent at a temperature of 90-200°C. According to the present invention, 2-hydroxy-6-ureidocarbonyl naphthalene derivative can easily be obtained within relatively short time and high yield.

  揭示了一种制备2-羟基-6-脲基羰基萘衍生物的方法。该方法包括在有机溶剂中以90-200°C的温度反应2-羟基-6-氨基羰基萘和异氰酸酯的步骤。根据本发明，可以在相对较短的时间内和高产率下轻松获得2-羟基-6-脲基羰基萘衍生物。
• [EN] ION CHANNEL ANTAGONISTS/BLOCKERS AND USES THEREOF<br/>[FR] ANTAGONISTES/BLOQUEURS DES CANAUX IONIQUES ET LEURS UTILISATIONS
  申请人：SHANGHAI EAST HOSPITAL

  公开号：WO2021114313A1

  公开（公告）日：2021-06-17

  Provided are ion channel antagonists/blockers and uses thereof. Specifically, it provides the compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs, preparation method therefor and application thereof. Definition of each group in the formula can be found in the specification for details. Provided is also pharmaceutical composition useful for treatment of heart disease and other ion channel related diseases.

  提供了离子通道拮抗剂/阻断剂及其用途。具体而言，提供了式（I）的化合物或药用盐、立体异构体、溶剂合物或前药，其制备方法及应用。每个式中的各个基团的定义可在说明书中找到详细信息。还提供了用于治疗心脏病和其他离子通道相关疾病的药物组合物。
• 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
  申请人：Wyeth

  公开号：US20030045560A1

  公开（公告）日：2003-03-06

  This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: 1 Wherein: Ar is phenyl, naphthyl, furanyl, benzofuranyl, indolyl, pyrazolyl, oxazolyl, fluorenyl, phenylcycloalkane where the cycloalkane can be cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl and Ar can be optionally substituted by 1 to 3 groups selected from C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, phenyl-(CH 2 ) 0-6 —, phenyl-(CH 2 ) 0-6 O—, C 3 -C 6 cycloalkyl, —(CH 2 )—C 3 -C 6 cycloalkyl, halogen, C 1 -C 3 perflouroalkyl and C 1 -C 3 perfluoroalkoxy where phenyl can be substituted with from 1 to 3 groups selected from C 1 -C 6 alkyl, C 1 -C 6 alkoxy, phenyl, halogen, trifluoromethyl or trifluoromethoxy; R 1 is hydrogen, C 1 -C 6 alkyl or phenyl-(CH 2 ) 1-6 — where phenyl can be substituted with C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo, trifluoromethyl or trifluoromethoxy; R 2 and R 3 are H, C 1 -C 6 alkyl, phenyl-(CH 2 ) 0-3 —, halo and C 1 -C 3 perfluoroalkyl where phenyl can be substituted with C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo, trifluoromethyl or trifluoromethoxy; R 4 is —CHR 5 CO 2 H or —CH 2 -tetrazole where R 5 is H or benzyl; and n=0 or 1; or a pharmaceutically acceptable salt or ester form thereof.

  这项发明提供了新颖的化合物、药物组合物和治疗哺乳动物血栓性疾病的方法，这些化合物具有以下结构式：1其中：Ar为苯基、萘基、呋喃基、苯并呋喃基、吲哚基、吡唑基、噁唑基、芴基、苯基环烷烃，其中环烷烃可以是环丙基、环丁基、环戊基或环己基，Ar可以选择性地被1至3个来自C1-C6烷基、C1-C6烷氧基、羟基、苯基-(CH2)0-6—、苯基-(CH2)0-6O—、C3-C6环烷基、—(CH2)—C3-C6环烷基、卤素、C1-C3全氟烷基和C1-C3全氟烷氧基的基团取代；R1为氢、C1-C6烷基或苯基-(CH2)1-6—，其中苯基可以被C1-C6烷基、C1-C6烷氧基、卤素、三氟甲基或三氟甲氧基取代；R2和R3为H、C1-C6烷基、苯基-(CH2)0-3—、卤素和C1-C3全氟烷基，其中苯基可以被C1-C6烷基、C1-C6烷氧基、卤素、三氟甲基或三氟甲氧基取代；R4为—CHR5CO2H或—CH2-四唑基，其中R5为H或苄基；n=0或1；或其药用可接受的盐或酯形式。
• [EN] NOVEL TETRAHYDROISOQUINOLINE COMPOUNDS FOR USE IN THE DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] NOUVEAUX COMPOSÉS DE TÉTRAHYDRO-ISOQUINOLINE POUR DIAGNOSTIC ET TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：UNIV BARI

  公开号：WO2012159666A1

  公开（公告）日：2012-11-29

  The invention relates to a new class of compounds with high affinity and selectivity towards P-glycoprotein. The invention also relates to the utilization of such compounds in the in vivo diagnosis of neurodegenerative diseases and as medicaments for use in the prevention and treatment of neurodegenerative disease involving P-glycoprotein.

  该发明涉及一类新的化合物，具有高亲和力和选择性，可用于P-糖蛋白。该发明还涉及利用这类化合物在体内诊断神经退行性疾病以及作为药物用于预防和治疗涉及P-糖蛋白的神经退行性疾病。